DPP4 and diabetes mellitus: Previous studies have shown that triazole derivatives, such as Sitagliptin, Voriconazole, and Fluconazole, have potential as diabetes drugs by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which indirectly reduces glucose levels by stimulating insulin secretion and inhibiting glucagon secretion [13, 14].